Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) effectively at boost the ...

Cancer cachexia is commonly present in various cancers, including live, pancreatic, gastroesophageal, and bile duct cancers, ...

NEO Battery Materials Ltd ( ($TSE:NBM) ) has shared an update. NEO Battery Materials has appointed University of Toronto associate professor and ...

Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Terzo remains on track for an interim data readout in early 2027, based on enrollment to date Achieved >30% annual growth in U.S. net sales of COPIKTRA™ through November BERKELEY HEIGHTS, N.J., Dec.

Marine bacteria are key to determining whether carbon is recycled near the ocean surface or transported to deeper waters, but ...

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in ...

P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a ...

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...

In vivo CAR T-cell therapy could revolutionize cancer treatment by bypassing traditional manufacturing, reducing costs, and minimizing adverse events. Kelonia Therapeutics' KLN-1010 has shown ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...